一种多价结合物调节雄激素受体转录活性,以抑制耐治疗的前列腺癌
Justine Habault1, Jeffrey A Schneider2, Susan Ha3
1Department of Microbiology, NYU Grossman School of Medicine, New York, New York.
Molecular cancer therapeutics
|July 24, 2023
概括
一种名为MPC309的新型多价值类合物 (MPC) 有效地抑制了抗割的前列腺癌 (CRPC). 这种新方法准了雄激素受体 (AR) 途径,显示出对抗耐药癌症模型的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 前列腺癌通常会对雄激素受体 (AR) 途径抑制剂产生抗性.
- 这种抗性是由持续的AR表达和功能驱动的,导致割耐性前列腺癌 (CRPC).
研究的目的:
- 开发和评估一种用于抑制CRPC的新型多价值类合物 (MPC).
- 为了研究MPC309的抗瘤作用,一种基于乙的特定MPC,对抗性前列腺癌模型.
主要方法:
- 合成MPC309,一种具有高AR结合亲和度的三价乙类结合类寡合体.
- 测试MPC309的抗增殖作用在各种抗酶胺的前列腺癌模型和小鼠有机体上.
- 通过巨型皮诺细胞酶分析细胞吸收并评估AR转录组,AR染色体占用率和协调蛋白相互作用.
- 与恩扎胺相比,在异种移植研究中评估瘤抑制.
主要成果:
- MPC309在各种抗性前列腺癌模型中表现出强大的抗增殖活性,包括具有AR变体和突变的前列腺癌模型.
- 细胞吸收通过癌症选择性巨细胞细胞形成.
- MPC309诱导了一种独特的AR基因表达特征,促进分化并抑制细胞分裂和新陈代谢.
- 在活体中,MPC309在抑制瘤生长方面显著优于恩扎胺.
结论:
- MPC309是一种有前途的新型雄激素受体 (AR) 调节器,用于对抗抗性前列腺癌.
- 它通过诱导抗增殖AR基因表达程序,有效地抑制CRPC.
- 它的选择性吸收机制为向瘤治疗提供了潜在的潜力.
更多相关视频
08:36Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
11.2K
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.9K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
01:15Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K